The immuno-oncology drug developer’s prospective initial public offering would mark exits for Takeda, Merck Group, Ipsen and Merck & Co.

Xilio Therapeutics, a US-based immuno-oncology drug developer backed by pharmaceutical firms Takeda, Merck & Co, Ipsen and Merck Group, has filed for an initial public offering on the Nasdaq Global Market.

Founded in 2016, Xilio is developing treatments that precisely target tumours to attack while minimising side effects. A $100m placeholder figure was given for the filing.

Proceeds from the offering would be used to take three of Xilio’s drug candidates – XTX101, XTX202 and XTX303 – through various…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn